Literature DB >> 23797059

The three α1-adrenoceptor subtypes show different spatio-temporal mechanisms of internalization and ERK1/2 phosphorylation.

M Perez-Aso1, V Segura, F Montó, D Barettino, M A Noguera, G Milligan, P D'Ocon.   

Abstract

We analyzed the kinetic and spatial patterns characterizing activation of the MAP kinases ERK 1 and 2 (ERK1/2) by the three α1-adrenoceptor (α1-AR) subtypes in HEK293 cells and the contribution of two different pathways to ERK1/2 phosphorylation: protein kinase C (PKC)-dependent ERK1/2 activation and internalization-dependent ERK1/2 activation. The different pathways of phenylephrine induced ERK phosphorylation were determined by western blot, using the PKC inhibitor Ro 31-8425, the receptor internalization inhibitor concanavalin A and the siRNA targeting β-arrestin 2. Receptor internalization properties were studied using CypHer5 technology and VSV-G epitope-tagged receptors. Activation of α1A- and α1B-ARs by phenylephrine elicited rapid ERK1/2 phosphorylation that was directed to the nucleus and inhibited by Ro 31-8425. Concomitant with phenylephrine induced receptor internalization α1A-AR, but not α1B-AR, produced a maintained and PKC-independent ERK phosphorylation, which was restricted to the cytosol and inhibited by β-arrestin 2 knockdown or concanavalin A treatment. α1D-AR displayed constitutive ERK phosphorylation, which was reduced by incubation with prazosin or the selective α1D antagonist BMY7378. Following activation by phenylephrine, α1D-AR elicited rapid, transient ERK1/2 phosphorylation that was restricted to the cytosol and not inhibited by Ro 31-8425. Internalization of the α1D-AR subtype was not observed via CypHer5 technology. The three α1-AR subtypes present different spatio-temporal patterns of receptor internalization, and only α1A-AR stimulation translates to a late, sustained ERK1/2 phosphorylation that is restricted to the cytosol and dependent on β-arrestin 2 mediated internalization.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AT(1A)R; Adrenaline α(1) receptors; BSA; Bmax; ConA; Constitutive activity; DMSO; EGFR; ERK1/2; G-protein coupled receptor; G-protein-coupled receptor kinase; GAPDH; GPCR; GRK; HEK; Internalization; KRH; Krebs Ringer Hepes; MAPK; PBST; PCR; PE; PKA; PKC; PTHR; PZ; angiotensin receptor type 1A; bovine serum albumin; concanavalin A; dimethyl sulfoxide; epidermal growth factor receptor; glyceraldehyde-3-phosphate dehydrogenase; human embryonic kidney; maximum number of binding sites; mitogen-activated protein kinase; parathyroid hormone receptor type 1; phenylephrine; phosphate-buffered saline with 0.1% Tween 20; polymerase chain reaction; prazosin; protein kinase A; protein kinase C; α(1) adrenoceptor; α(1)-AR; β(2) adrenoceptor; β(2)-AR

Mesh:

Substances:

Year:  2013        PMID: 23797059     DOI: 10.1016/j.bbamcr.2013.06.013

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  15 in total

Review 1.  Localization of α-adrenoceptors: JR Vane Medal Lecture.

Authors:  John C McGrath
Journal:  Br J Pharmacol       Date:  2015-03       Impact factor: 8.739

Review 2.  Updates in the function and regulation of α1 -adrenoceptors.

Authors:  Juliana Akinaga; J Adolfo García-Sáinz; André S Pupo
Journal:  Br J Pharmacol       Date:  2019-04-01       Impact factor: 8.739

3.  Factors influencing biased agonism in recombinant cells expressing the human α1A -adrenoceptor.

Authors:  Edilson Dantas da Silva Junior; Masaaki Sato; Jon Merlin; Natalie Broxton; Dana S Hutchinson; Sabatino Ventura; Bronwyn A Evans; Roger J Summers
Journal:  Br J Pharmacol       Date:  2017-06-10       Impact factor: 8.739

4.  Heterologous phosphorylation-induced formation of a stability lock permits regulation of inactive receptors by β-arrestins.

Authors:  András D Tóth; Susanne Prokop; Pál Gyombolai; Péter Várnai; András Balla; Vsevolod V Gurevich; László Hunyady; Gábor Turu
Journal:  J Biol Chem       Date:  2017-11-16       Impact factor: 5.157

5.  Receptor Species-dependent Desensitization Controls KCNQ1/KCNE1 K+ Channels as Downstream Effectors of Gq Protein-coupled Receptors.

Authors:  Marie-Cécile Kienitz; Dilyana Vladimirova; Christian Müller; Lutz Pott; Andreas Rinne
Journal:  J Biol Chem       Date:  2016-11-10       Impact factor: 5.157

6.  Carboxyl terminus-truncated α1D-adrenoceptors inhibit the ERK pathway.

Authors:  Marco A Alfonzo-Méndez; Jean A Castillo-Badillo; M Teresa Romero-Ávila; Richard Rivera; Jerold Chun; J Adolfo García-Sáinz
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-05-05       Impact factor: 3.000

7.  PACAP-induced ERK activation in HEK cells expressing PAC1 receptors involves both receptor internalization and PKC signaling.

Authors:  Victor May; Thomas R Buttolph; Beatrice M Girard; Todd A Clason; Rodney L Parsons
Journal:  Am J Physiol Cell Physiol       Date:  2014-04-02       Impact factor: 4.249

8.  Measuring agonist-induced ERK MAP kinase phosphorylation for G-protein-coupled receptors.

Authors:  Punita Kumari; Hemlata Dwivedi; Mithu Baidya; Arun K Shukla
Journal:  Methods Cell Biol       Date:  2018-11-19       Impact factor: 1.441

9.  Isoproterenol acts as a biased agonist of the alpha-1A-adrenoceptor that selectively activates the MAPK/ERK pathway.

Authors:  Alicja J Copik; Aleksander Baldys; Khanh Nguyen; Sunil Sahdeo; Hoangdung Ho; Alan Kosaka; Paul J Dietrich; Bill Fitch; John R Raymond; Anthony P D W Ford; Donald Button; Marcos E Milla
Journal:  PLoS One       Date:  2015-01-21       Impact factor: 3.240

10.  Cross-talk between alpha1D-adrenoceptors and transient receptor potential vanilloid type 1 triggers prostate cancer cell proliferation.

Authors:  Maria Beatrice Morelli; Consuelo Amantini; Massimo Nabissi; Sonia Liberati; Claudio Cardinali; Valerio Farfariello; Daniele Tomassoni; Wilma Quaglia; Alessandro Piergentili; Alessandro Bonifazi; Fabio Del Bello; Matteo Santoni; Gabriele Mammana; Lucilla Servi; Alessandra Filosa; Angela Gismondi; Giorgio Santoni
Journal:  BMC Cancer       Date:  2014-12-07       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.